BLASUBCUTANEOUSVIALPriority Review
Approved
Jul 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
38
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETASERON (interferon beta-1b) is a recombinant cytokine therapeutic administered subcutaneously, approved in 1993 for multiple sclerosis and several other indications including clinically isolated syndrome, cardiomyopathy, and HIV-related conditions. As an immunomodulatory agent, it functions by enhancing natural killer cell activity and increasing expression of MHC antigens to reduce inflammation and slow disease progression. The product is positioned as a foundational MS disease-modifying therapy, though it faces significant competition from newer oral and monoclonal antibody approaches.
$0.1BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (38)
US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector
Started Nov 2020
100 enrolled
Multiple Sclerosis
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
Started Sep 2017
96 enrolled
Multiple Sclerosis
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
Started Feb 2016
146 enrolled
Multiple Sclerosis, Relapsing-Remitting
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Started Sep 2015
162 enrolled
Multiple Sclerosis
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
Started Oct 2014
498 enrolled
Multiple Sclerosis, Relapsing Remitting
Worked on BETASERON at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.